Nat Commu:PARP抑制剂成功阻断前列腺癌的复发

2017-09-06 佚名 medicalxpress

可以减少男性患前列腺癌复发的开创性的研究近日发表在《自然》杂志上。抗荷尔蒙疗法是治疗前列腺癌的常见方法,有助于通过降低雄性激素的水平,来阻断肿瘤生长。在这个深入的研究中,一个由英国科学家领导的国际小组调查了抗荷尔蒙治疗对前列腺癌患者样本的影响。

可以减少男性患前列腺癌复发的开创性的研究近日发表在《自然》杂志上。抗荷尔蒙疗法是治疗前列腺癌的常见方法,有助于通过降低雄性激素的水平,来阻断肿瘤生长。在这个深入的研究中,一个由英国科学家领导的国际小组调查了抗荷尔蒙治疗对前列腺癌患者样本的影响。

研究人员发现了一个意外的结果,抗荷尔蒙疗法治疗能激活DNA修复PARP酶,而PARP使癌细胞能承受荷尔蒙疗法治疗,这就导致细胞发展成一个更具有攻击性的形式。因此,抑制PARP可以有效阻止前列腺癌的复发,处方PARP抑制剂是常用于治疗乳腺癌的药物,结合抗荷尔蒙疗法治疗前列腺癌,可能会让患者受益,因为PARP抑制剂防止DNA修复,导致癌症细胞自行灭亡。

此次研究负责人表示:“前列腺癌是一种毁灭性的癌症,死亡率很高,我们惊喜的发现了有助于缓解前列腺癌发展和复发的好方法,相信可以很大程度的增加前列腺癌的生存几率。我们的研究表明,抗荷尔蒙疗法可以与PARP抑制剂结合在一起来阻止疾病的进展。”

研究人员补充说,“这个早期阶段的研究发现了很多的证据,说明前列腺癌患者可能受益于PARP抑制剂与激素治疗。下一步是进行临床试验,测试结合治疗的安全性,一旦通过,就可以帮助更多的人阻止这一致命疾病的发生。”

原始出处:

Mohammad Asim, Firas Tarish, Heather I. Zecchini, et.al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications 8

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851521, encodeId=63301851521cb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 02 14:55:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710100, encodeId=1d421e10100dd, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Apr 22 09:55:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882428, encodeId=98601882428d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 06 21:55:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621317, encodeId=afa3162131e3b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Thu Sep 07 23:55:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2018-05-02 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851521, encodeId=63301851521cb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 02 14:55:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710100, encodeId=1d421e10100dd, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Apr 22 09:55:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882428, encodeId=98601882428d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 06 21:55:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621317, encodeId=afa3162131e3b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Thu Sep 07 23:55:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851521, encodeId=63301851521cb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 02 14:55:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710100, encodeId=1d421e10100dd, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Apr 22 09:55:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882428, encodeId=98601882428d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 06 21:55:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621317, encodeId=afa3162131e3b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Thu Sep 07 23:55:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2018-04-06 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851521, encodeId=63301851521cb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 02 14:55:00 CST 2018, time=2018-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710100, encodeId=1d421e10100dd, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sun Apr 22 09:55:00 CST 2018, time=2018-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882428, encodeId=98601882428d9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 06 21:55:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621317, encodeId=afa3162131e3b, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Thu Sep 07 23:55:00 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-09-07 lishiwen

相关资讯

Oncotarget:Aurora A激酶通过调节DNA修复与卵巢癌治疗相关

卵巢癌发病隐匿,发现时往往已是疾病的晚期。手术治疗难以达到满意的疗效,化疗一般疗程长,副反应重,患者很难承受,且容易出现耐药。Aurora A激酶(AURKA)是极光激酶家族成员之一,为蛋白质丝氨酸/苏氨酸激酶,其通过调节有丝分裂和染色体不稳定性在卵巢癌的发展过程中起重要作用。PARP是细胞凋亡核心成员半胱天冬酶(caspase)的切割底物,它在DNA损伤修复与细胞凋亡中发挥着重要作用。

PLoS ONE:一群或可鉴定卵巢癌的缺陷蛋白

俄勒冈健康与科学大学(OHSU)Knight癌症研究所的研究发现,一群有缺陷的蛋白质,被怀疑导致了机体修复自身DNA能力的故障,科学家们可能正好需要这群蛋白来证明一类新药在治疗广泛的卵巢癌患者中的有效性。 这些研究结果发表在这周的PLoS ONE上,已引发更多关于靶向聚腺苷二磷酸核糖聚合酶(PARP)药物临床试验中病人人数是否应该扩大的探讨。一些类型癌症的生长比正常细胞更依赖于PARP,这就意味

Nat Med:20% 乳腺癌患者中可以 PARP 抑制剂治疗治疗中获益

来自 Wellcome Trust Sanger 研究所的研究人员及其合作者已经发现,更多数量的乳腺癌在遗传上类似于具有错误的 BRCA1 或 BRCA2 基因的罕见病例。今天(3 月 13 日)在 Nature Medicine 上发表的结果揭示了高达 20%的妇女接受 PARP 抑制剂治疗的可能性,PARP 抑制剂是一种以前仅被认为对具有遗传性 BRCA1 或 BRCA2 突变的妇女有效的药物

Nat Rev Drug Discov:欧洲监管机构批准的第一个PARP抑制剂

在2011年和2012年,一系列临床试验的失败威胁着聚腺苷二磷酸-核糖聚合酶(PARP)抑制剂——调节DNA损伤的修复,这类抑制剂濒临灭绝。不仅赛诺菲的iniparib在三阴性乳腺癌的失败,而且阿斯利康的奥拉帕尼对抗卵巢癌也令人失望。随后的研究表明,iniparib 不是一个功能性的PARP抑制剂以及进一步揭示了病人的选择,推动了退缩(Nature Rev. Drug Discov. 12, 72